Ig replacement therapy ‘beneficial’ for patients with blood cancers
Reduction seen in hypogammaglobulinaemia, infections, and associated antimicrobial use.
Immunoglobulin replacement therapy is associated with reductions in hypogammaglobulinaemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukaemia or non-Hodgkin’s lymphoma, according to a study in Blood Advances.
Dr Jacob D Soumerai, from the Massachusetts General Hospital Cancer Center in Boston, and colleagues examined patterns of immunoglobulin G (IgG) testing and the effectiveness of immunoglobulin replacement therapy in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin’s lymphoma (NHL) in a retrospective, longitudinal study.
